MP02-14 AN EVALUATION OF THE FEDERAL ADVERSE EVENTS REPORTING SYSTEM DATA ON ADVERSE EFFECTS OF OVERACTIVE BLADDER MEDICATIONS
نویسندگان
چکیده
You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Non-neurogenic Voiding Dysfunction I (MP02)1 Sep 2021MP02-14 AN EVALUATION OF THE FEDERAL ADVERSE EVENTS REPORTING SYSTEM DATA ON EFFECTS OVERACTIVE BLADDER MEDICATIONS Siri Drangsholt, Michelina Stoddard, Stephanie Sansone, Ahra Cho, and Bilal Chughtai DrangsholtSiri Drangsholt More articles by this author , StoddardMichelina Stoddard SansoneStephanie Sansone ChoAhra Cho ChughtaiBilal View All Author Informationhttps://doi.org/10.1097/JU.0000000000001963.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To investigate the side effects associated with exposure overactive bladder medications in post marketing world. METHODS: The FDA’s safety surveillance program (FAERs) for antimuscarinic B agonist was analyzed from January 2005 December 2019. Reports identified one or more adverse effects. Cases monotherapy primary were identified. frequency reactions summarized between various drugs dosages. Reporter type age patients collected. RESULTS: A total 19,607 case reports obtained. 13,328 antimuscarinics (combined) 6279 agonists. average patient 71.8 years (SD-13.6), 63% all filed a non-health care professional. On per drug basis, oxybutynin (n=8,083) followed mirabegron (n=6,279) had highest number events trospium (n=186) lowest. Neuropsychiatric constitutional reported greatest (see Table 1). Oxybutynin most 2014 2,777 reports, submitted 2018 901 reports. CONCLUSIONS: Analysis FAERS data showed medications. causality rate AEs are not certain based on data. Source Funding: None © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e17-e17 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...
منابع مشابه
Reporting of adverse events.
From the Harvard School of Public Health, Boston. HEN the Institute of Medicine (IOM) issued To Err Is Human,1 the recommendation to expand reporting of serious adverse events and medical errors, particularly mandatory reporting, received the most attention and sparked controversy.2 The American Medical Association and the American Hospital Association raised strong objections, claiming that ma...
متن کاملChoosing appropriate theories for understanding hospital reporting of adverse drug events, a theoretical domains framework approach
Adverse drug events (ADEs) may cause serious injuries including death. Spontaneous reporting of ADEs plays a great role in detection and prevention of them, however, underreporting always exists. Although several interventions have been utilized to solve this problem, they are mainly based on experience and the rationale for choosing them has no theoretical base. The vast variety of behavioral ...
متن کاملAn evaluation of adverse incident reporting.
To examine the reliability of adverse incident-reporting systems we carried out a retrospective review of the mother and baby case notes from a series of 250 deliveries in each of two London obstetric units. Notes were screened for the presence of adverse incidents defined by lists of incidents to be reported in accordance with unit protocols. We assessed the percentage of adverse incidents rep...
متن کاملStatin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
OBJECTIVE Adverse event reports (AERs) submitted to the US Food and Drug Administration (FDA) were reviewed to assess the muscular and renal adverse events induced by the administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) and to attempt to determine the rank-order of the association. METHODS After a revision of arbitrary drug names and the deletio...
متن کاملAdverse events reporting--the tip of an iceberg.
NIH data indicate that annually seven million human subjects are enrolled in research sponsored by NIH alone. In addition, there are sixteen federal agencies and numerous departments outside NIH conducting experiments with human subjects. Moreover, the pharmaceutical industry spends $26 billion on research (compared to $16 billion for NIH), thus, the total number of human subjects enrolled in r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Urology
سال: 2021
ISSN: ['0022-5347', '1527-3792']
DOI: https://doi.org/10.1097/ju.0000000000001963.14